Tiziana submits FDA investigational new drug application
Portfolio Pulse from
Tiziana Life Sciences Ltd has filed an investigational new drug application with the FDA for a phase two clinical trial in Amyotrophic Lateral Sclerosis (ALS) using its lead candidate, intranasal foralumab. The trial will include 20 patients upon clearance.
March 04, 2025 | 2:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Tiziana Life Sciences has submitted an FDA application for a phase two trial in ALS, potentially advancing its lead candidate, intranasal foralumab.
The submission of an FDA application for a phase two trial is a significant step for Tiziana Life Sciences, indicating progress in their drug development pipeline. This could positively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100